Received Feb 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
vaccine was inadvertently administered sooner than recommended timeframe; This non-serious case was reported by a nurse via sales rep and described the occurrence of drug administration duration too short in a 10-year-old patient who received HAV (Havrix) for prophylaxis. Previously administered products included Havrix (Received first dose on unknown date). On an unknown date, the patient received the 2nd dose of Havrix. On an unknown date, an unknown time after receiving Havrix, the patient experienced drug administration duration too short (Verbatim: vaccine was inadvertently administered sooner than recommended timeframe). The outcome of the drug administration duration too short was unknown. Additional Information: GSK Receipt Date: 16-JAN-2025 The reporter reported that a patient received Havrix booster dose given less than 6 months which led to drug administration duration too short. A vaccine was inadvertently administered sooner than recommended timeframe, specifically for the Havrix (hepatitis A). Reporter was waiting for nurse manager to get back with more information.